Cagrilintide Dose Escalation Studies Phase 2 trials evaluated multiple cagrilintide doses to identify the optimal balance between efficacy and tolerability: 0.3 mg weekly Minimal efficacy, excellent tolerability 0.6 mg weekly Moderate effects, good tolerability 1.2 mg weekly Strong efficacy, acceptable side effects 2.4 mg weekly Optimal efficacy-tolerability balance 4.5 mg weekly Excessive GI side effects outweighed benefits The 2.4 mg weekly dose emerged as the standard in phase 3 trials, providing substantial metabolic benefits while maintaining an acceptable side effect profile[6]
Journal of Orthopaedic Research , 1999
First discovered in the 1970s, GHK-Cu has been extensively studied for its regenerative properties, particularly in skin health and wound healing
For eye-area products, 2% is more appropriate because the skin around the eyes is thinner and more reactive
Store refrigerated to maintain potency and stability
2 4 From a regulatory standpoint, GHK-Cu sits firmly in the cosmetic and research categories, not the pharmaceutical one